Tariq Ahmad

List of Publications by Year
in descending order

131	3,420	172207	168136
papers	citations	29 h-index	53 g-index

131	131	131	5280
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Trends in Heart Failure Hospitalizations in the US from 2008 to 2018. Journal of Cardiac Failure, 2022, 28, 171-180.	0.7	40
2	Trends in transcatheter and surgical aortic valve replacement in the United States, 2008-2018. American Heart Journal, 2022, 243, 87-91.	1.2	13
3	Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF). American Heart Journal, 2022, 244, 107-115.	1.2	12
4	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008594.	1.6	7
5	Nudging within learning health systems: next generation decision support to improve cardiovascular care. European Heart Journal, 2022, 43, 1296-1306.	1.0	16
6	Reimagining Evidence Generation for Heart Failure and the Role of Integrated Health Care Systems. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, CIRCOUTCOMES121008292.	0.9	8
7	Electronic Alerts to Improve HeartÂFailure Therapy in Outpatient Practice. Journal of the American College of Cardiology, 2022, 79, 2203-2213.	1.2	86
8	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. Progress in Cardiovascular Diseases, 2022, , .	1.6	1
9	Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	3
10	Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation: Heart Failure, 2021, 14, e007759.	1.6	3
11	Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. PLoS ONE, 2021, 16, e0247789.	1.1	11
12	Setting the Stage for a Multimarker-Based HeartÂFailure Prevention Trial?. JACC: Heart Failure, 2021, 9, 224-225.	1.9	0
13	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. European Cardiology Review, 2021, 16, e11.	0.7	2
14	Left Ventricular Assist Devices Versus Heart Transplantation for End Stage HeartÂFailure is a Misleading Equivalency. JACC: Heart Failure, 2021, 9, 290-292.	1.9	9
15	Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 447-455.	1.2	7
16	Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circulation: Heart Failure, 2021, 14, e008335.	1.6	113
17	Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials. Journal of Cardiac Failure, 2021, 27, 602-606.	0.7	13
18	Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). American Journal of Cardiology, 2021, 146, 99-106.	0.7	25

#	Article	IF	Citations
19	Outcomes in patients with anthracyclineâ€induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure, 2021, 8, 2866-2875.	1.4	7
20	Extreme High Insulin Requirements in Two Non-Diabetic Patients Following Cardiac Transplantation. Journal of the Endocrine Society, 2021, 5, A383-A383.	0.1	0
21	Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes. ESC Heart Failure, 2021, 8, 2741-2754.	1.4	32
22	Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC: Heart Failure, 2021, 9, 420-429.	1.9	64
23	Comparison of Transcatheter and Open Mitral Valve Repair Among Patients With Mitral Regurgitation. Mayo Clinic Proceedings, 2021, 96, 1522-1529.	1.4	1
24	The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. Journal of Cardiac Failure, 2021, 27, 1359-1366.	0.7	2
25	REVeAL-HF. JACC: Heart Failure, 2021, 9, 409-419.	1.9	14
26	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With HeartÂFailure. JACC: Heart Failure, 2021, 9, 497-505.	1.9	5
27	Reply. JACC: Heart Failure, 2021, 9, 532.	1.9	0
28	Electronic health record risk score provides earlier prognostication of clinical outcomes in patients admitted to the cardiac intensive care unit. American Heart Journal, 2021, 238, 85-88.	1.2	5
29	Mechanical ventilation at the time of heart transplantation and associations with clinical outcomes. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 843-851.	0.4	8
30	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. JACC: Heart Failure, 2021, 9, 568-577.	1.9	8
31	Electrocardiogram Findings in Patients with Alopecia Areata. Dermatology and Therapy, 2021, 11, 2217-2223.	1.4	0
32	Brief report: Cannabis and opioid use disorder among heart failure admissions, 2008â€“2018. PLoS ONE, 2021, 16, e0255514.	1.1	3
33	Cannabis use disorder among atrial fibrillation admissions, 2008â€“2018. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1934-1938.	0.5	2
34	Trends and Outcomes of Cardiac Transplantation in the Lowest Urgency Candidates. Journal of the American Heart Association, 2021, 10, e023662.	1.6	5
35	Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement. ASAIO Journal, 2021, 67, 650-657.	0.9	3
36	The influence of comorbidities on achieving an Nâ€terminal proâ€bâ€type natriuretic peptide target: a secondary analysis of the GUIDEâ€IT trial. ESC Heart Failure, 2021, , .	1.4	3

#	Article	IF	Citations
37	Multisystem inflammatory syndrome in adults (MIS-A) associated with SARS-CoV-2 infection with delayed-onset myocarditis: case report. European Heart Journal - Case Reports, 2021, 5, ytab470.	0.3	10
38	Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 12-21.	1.9	152
39	HeartÂFailure With PreservedÂEjectionÂFraction. JACC: Heart Failure, 2020, 8, 185-187.	1.9	1
40	Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. American Journal of Cardiology, 2020, 133, 116-125.	0.7	13
41	Use and outcomes of wearable cardioverter-defibrillators in a large integrated academic health system. American Heart Journal, 2020, 226, 232-234.	1.2	0
42	Transition to Advanced Therapies in Elderly Patients Supported by Extracorporeal Membrane Oxygenation Therapy. Journal of Cardiac Failure, 2020, 26, 1086-1089.	0.7	11
43	Conduct of Clinical Trials in the Era of COVID-19. Journal of the American College of Cardiology, 2020, 76, 2368-2378.	1.2	35
44	Quadruple Therapy Is the New Standard of Care for HFrEF. JACC: Heart Failure, 2020, 8, 819-821.	1.9	13
45	Evaluation of Case Volumes of a Heart Transplant Program and Short-term Outcomes After Changes in the United Network for Organ Sharing Donor Heart Allocation System. JAMA Network Open, 2020, 3, e2017513.	2.8	14
46	Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. American Heart Journal, 2020, 230, 54-58.	1.2	1
47	Sex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage HeartÂFailure. JACC: Heart Failure, 2020, 8, 770-779.	1.9	36
48	Empagliflozin in Heart Failure. Circulation, 2020, 142, 1028-1039.	1.6	252
49	Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. Cardiovascular Endocrinology and Metabolism, 2020, 9, 56-59.	0.5	20
50	Under Our Very Eyes. New England Journal of Medicine, 2020, 382, 952-957.	13.9	1
51	Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation. Journal of Heart and Lung Transplantation, 2020, 39, 926-933.	0.3	21
52	Psychiatric Comorbidity and Outcomes After Left Ventricular Assist Device Implantation for End-Stage HeartÂFailure. JACC: Heart Failure, 2020, 8, 569-577.	1.9	10
53	Safety of compression therapy for venous ulcer disease in the setting of congestive heart failure. Phlebology, 2020, 35, 556-560.	0.6	5
54	Adoption of sacubitril-valsartan in the Medicare population. American Heart Journal, 2020, 223, 81-83.	1.2	1

#	Article	IF	Citations
55	Real World Use of Hypertonic Saline in Refractory Acute Decompensated HeartÂFailure. JACC: Heart Failure, 2020, 8, 199-208.	1.9	59
56	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. JAMA Cardiology, 2020, 5, 757.	3.0	74
57	A Novel Treatment for a Rare Cause of Cardiogenic Shock. JACC: Case Reports, 2020, 2, 1461-1465.	0.3	5
58	Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures. PLoS ONE, 2020, 15, e0230734.	1.1	1
59	COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. PLoS ONE, 2020, 15, e0238829.	1.1	21
60	Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLoS ONE, 2020, 15, e0242928.	1.1	9
61	Title is missing!. , 2020, 15, e0230734.		0
62	Title is missing!. , 2020, 15, e0230734.		0
63	Title is missing!. , 2020, 15, e0230734.		0
64	Title is missing!. , 2020, 15, e0230734.		0
65	Title is missing!. , 2020, 15, e0230734.		0
66	Title is missing!. , 2020, 15, e0230734.		0
67	Title is missing!. , 2020, 15, e0238829.		0
68	Title is missing!. , 2020, 15, e0238829.		0
69	Title is missing!. , 2020, 15, e0238829.		0
70	Title is missing!. , 2020, 15, e0238829.		0
71	Can advanced analytics fix modern medicine's problem of uncertainty, imprecision, and inaccuracy?. European Journal of Heart Failure, 2019, 21, 86-89.	2.9	0
72	Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. European Journal of Heart Failure, 2019, 21, 1064-1078.	2.9	79

#	Article	IF	Citations
73	National Trends in Healthcare-Associated Infections for Five Common Cardiovascular Conditions. American Journal of Cardiology, 2019, 124, 1140-1148.	0.7	17
74	National Trends in Incidence and Outcomes of Patients With Heart Failure Requiring Respiratory Support. American Journal of Cardiology, 2019, 124, 1712-1719.	0.7	13
75	Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). American Journal of Cardiology, 2019, 123, 1193-1201.	0.7	7
76	Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. Circulation: Heart Failure, 2019, 12, e005552.	1.6	43
77	Natriuretic Response Is Highly Variable and Associated With 6-Month Survival. JACC: Heart Failure, 2019, 7, 383-391.	1.9	51
78	Acute Decompensated Heart Failure Complicated by Respiratory Failure. Circulation: Heart Failure, 2019, 12, e006013.	1.6	20
79	Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004983.	0.9	19
80	Predictive Abilities of Machine Learning Techniques May Be Limited by Dataset Characteristics: Insights From the UNOS Database. Journal of Cardiac Failure, 2019, 25, 479-483.	0.7	48
81	Improving Outcomes in INTERMACS Category 1 Patients with Pre-LVAD, Awake Venous-Arterial Extracorporeal Membrane Oxygenation Support. ASAIO Journal, 2019, 65, 819-826.	0.9	22
82	Clinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure. Circulation: Heart Failure, 2019, 12, e006369.	1.6	13
83	Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults. JACC: Heart Failure, 2019, 7, 1069-1078.	1.9	25
84	Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Reports, 2019, 5, 1018-1026.	0.4	24
85	Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. Journal of the American Heart Association, 2018, 7, .	1.6	153
86	Variation in practice patterns and outcomes across United Network for Organ Sharing allocation regions. Clinical Cardiology, 2018, 41, 81-86.	0.7	3
87	Essential Elements of Early Post Discharge Care of Patients with Heart Failure. Current Heart Failure Reports, 2018, 15, 181-190.	1.3	7
88	Inflammation and cardioâ€renal interactions in heart failure: a potential role for interleukinâ€6. European Journal of Heart Failure, 2018, 20, 933-934.	2.9	24
89	The Twittersphere Needs AcademicÂCardiologists!. JACC: Heart Failure, 2018, 6, 172-173.	1.9	11
90	National Landscape of Unplanned 30-Day Readmissions in Patients With Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2018, 122, 261-267.	0.7	12

#	Article	IF	Citations
91	Loop diuretics in heart failure: Few facts and lots of prejudice. American Heart Journal, 2018, 205, 131-132.	1.2	1
92	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. Circulation: Heart Failure, 2018, 11, e004926.	1.6	26
93	The Trifecta of Precision Care in HeartÂFailure. Journal of the American College of Cardiology, 2018, 72, 1091-1094.	1.2	11
94	Combating Acute Heart Failure inÂtheÂArena. JACC: Heart Failure, 2018, 6, 871-873.	1.9	1
95	Haemoconcentration as a treatment goal in heart failure: ready for prime time?. European Journal of Heart Failure, 2017, 19, 237-240.	2.9	3
96	Physical Activity Prevents Obesity andÂHeart Failure. JACC: Heart Failure, 2017, 5, 385-387.	1.9	2
97	What happens to stable heart failure patients when they don't take their medicines?. European Journal of Heart Failure, 2017, 19, 650-651.	2.9	0
98	National Trends in Use and Outcomes of Pulmonary Artery Catheters Among Medicare Beneficiaries, 1999-2013. JAMA Cardiology, 2017, 2, 908.	3.0	54
99	Breaking Bad. JACC: Heart Failure, 2017, 5, 446-448.	1.9	5
100	Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis. Pulmonary Circulation, 2017, 7, 486-493.	0.8	12
101	An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial. International Journal of Cardiology, 2017, 241, 277-282.	0.8	27
102	A Blueprint for the Post Discharge Clinic Visit after an Admission for Heart Failure. Progress in Cardiovascular Diseases, 2017, 60, 237-248.	1.6	11
103	Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2017, 14, 434-443.	1.3	15
104	Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. PLoS Medicine, 2016, 13, e1002007.	3.9	55
105	Reduced Cardiac Index Is Not theÂDominant Driver of RenalÂDysfunctionÂinÂHeart Failure. Journal of the American College of Cardiology, 2016, 67, 2199-2208.	1.2	98
106	Hypochloremia and Diuretic Resistance in Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	102
107	Can Big Data Simplify the ComplexityÂofÂModern Medicine?. JACC: Heart Failure, 2016, 4, 722-725.	1.9	8
108	Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical CirculatoryÂSupport. Journal of the American College of Cardiology, 2016, 67, 291-299.	1.2	143

#	Article	IF	Citations
109	Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. PLoS ONE, 2016, 11, e0145881.	1.1	30
110	Disentangling the association between statins, cholesterol, and colorectal cancer: A nested case-control study.. Journal of Clinical Oncology, 2016, 34, 3609-3609.	0.8	6
111	Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy?. European Journal of Heart Failure, 2015, 17, 647-651.	2.9	2
112	Reclassifying heart failure: time for disruptive innovation?. European Journal of Heart Failure, 2015, 17, 879-880.	2.9	4
113	Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, FluidÂHomeostasis, Inflammation, and Renal Injury. JACC: Heart Failure, 2015, 3, 30-39.	1.9	70
114	Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 709-716.	1.6	9
115	Use of outcome measures in pulmonary hypertension clinical trials. American Heart Journal, 2015, 170, 419-429.e3.	1.2	17
116	Wherein Lies the Balance Between CaringÂand Detachment?. Journal of the American College of Cardiology, 2015, 65, 1481-1483.	1.2	5
117	The Heart Is Just a Muscle. Circulation, 2015, 131, 914-922.	1.6	1
118	The Role of Sodium and Chloride inÂHeartÂFailure. Journal of the American College of Cardiology, 2015, 66, 667-669.	1.2	19
119	The Current and Potential Clinical Relevance of Heart Failure Biomarkers. Current Heart Failure Reports, 2015, 12, 318-327.	1.3	10
120	Relationship Between Galectin-3 Levels and Mineralocorticoid Receptor Antagonist Use in Heart Failure: Analysis From HF-ACTION. Journal of Cardiac Failure, 2014, 20, 38-44.	0.7	28
121	The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. American Heart Journal, 2014, 167, 193-202.e1.	1.2	50
122	Clinical Implications of ChronicÂHeartÂFailure Phenotypes DefinedÂbyÂCluster Analysis. Journal of the American College of Cardiology, 2014, 64, 1765-1774.	1.2	197
123	Treatment for low-risk patients with STEMIâ€"challenges remain. Nature Reviews Cardiology, 2014, 11, 440-442.	6.1	0
124	Potential Applications of Pharmacogenomics to Heart Failure Therapies. Heart Failure Clinics, 2014, 10, 599-606.	1.0	4
125	Rationale and Design of theÂGUIDE-ITÂStudy. JACC: Heart Failure, 2014, 2, 457-465.	1.9	106
126	Challenges Facing Early Career Academic Cardiologists. Journal of the American College of Cardiology, 2014, 63, 2199-2208.	1.2	51

#	Article	IF	Citations
127	Charting a Roadmap for Heart Failure Biomarker Studies. JACC: Heart Failure, 2014, 2, 477-488.	1.9	81
128	Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. JACC: Heart Failure, 2014, 2, 260-268.	1.9	104
129	When the Heart Runs Out of Heartbeats. Circulation, 2012, 125, 2948-2955.	1.6	30
130	Lifestyle Interaction With Fat Mass and Obesity-Associated (FTO) Genotype and Risk of Obesity in Apparently Healthy U.S. Women. Diabetes Care, 2011, 34, 675-680.	4.3	84
131	The Fat-Mass and Obesity-Associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. American Heart Journal, 2010, 160, 1163-1169.	1.2	51